Actively Recruiting
Post-Exablate Pregnancy Outcomes Registry Study: Exablate Treatment of Symptomatic Uterine Fibroids
Led by InSightec · Updated on 2025-04-30
200
Participants Needed
6
Research Sites
567 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this Registry Study is to capture clinical pregnancy outcomes and fibroid treatment background data for any subject post-Exablate treatment for their symptomatic fibroids.
CONDITIONS
Official Title
Post-Exablate Pregnancy Outcomes Registry Study: Exablate Treatment of Symptomatic Uterine Fibroids
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Eligibility follows the symptomatic fibroids device indication.
- All patients who consent to the registry after treatment of their fibroid(s) with the Exablate system.
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 6 locations
1
UCLA
Los Angeles, California, United States, 90095
Actively Recruiting
2
Stanford University
Stanford, California, United States, 94305
Actively Recruiting
3
Mayo Clinic
Rochester, Minnesota, United States, 55905
Actively Recruiting
4
Huashan Hospital Affiliated to Fudan University
Shanghai, China
Active, Not Recruiting
5
Shanghai No. 1 Hospital
Shanghai, China
Actively Recruiting
6
Shanghai No.1 Hospital
Shanghai, China
Actively Recruiting
Research Team
N
Nadir Alikacem
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here